Published in:
01-02-2017 | Erratum
Erratum to: Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer
Published in: International Journal of Clinical Oncology | Issue 1/2017
Login to get accessExcerpt
In the original publication of the article, Table 4 was published incorrectly. The corrected Table 4 is published with this erratum.
Table 4
Treatment-related adverse events, all grades (≥30 %) and grade ≥3
|
All grades (≥30 %)
|
Grade ≥3
|
|
|---|---|---|
|
Rash
|
85 (82.5)
|
15 (14.6)
|
|
Diarrhea
|
82 (79.6)
|
1 (1.0)
|
|
Dry skin
|
82 (79.6)
|
5 (4.9)
|
|
Paronychia
|
69 (67.0)
|
1 (1.0)
|
|
Stomatitis
|
65 (63.1)
|
1 (1.0)
|
|
Pruritus
|
67 (65.0)
|
3 (2.9)
|
|
Decreased appetite
|
35 (34.0)
|
2 (1.9)
|
|
ALT increased
|
33 (32.0)
|
9 (8.7)
|